Do corticosteroids improve outcome for any critical illness?

Current Opinion in Anaesthesiology

Volumn 26, Issue 2, 2013, Pages 164-170

  Batzofin, Baruch M ^a   Weiss, Yoram G ^a   Ledot, Stephane F ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

acute respiratory distress syndrome; corticosteroids; sepsis; steroids

Indexed keywords

CORTICOSTEROID; ETOMIDATE; HYDROCORTISONE; METHYLPREDNISOLONE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; COMMUNITY ACQUIRED MENINGITIS; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG MEGADOSE; EARLY INTERVENTION; HUMAN; IMMUNOMODULATION; INFECTION; INTENSIVE CARE; ISCHEMIA; LENGTH OF STAY; LOW DRUG DOSE; MENINGITIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; SEPSIS; SEPTIC SHOCK; SPINAL CORD INJURY; SUPERINFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE INJURY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MENINGITIS; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK, SEPTIC; SPINAL CORD INJURIES;

EID: 84874950742     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32835e820e     Document Type: Review

References (57)

1. Scott WJ. The influence of the adrenal glands on resistance: II. The toxic effect of killed bacteria in adrenalectomized rats. J Exp Med 1924; 39:457.
2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150.
3. Meduri GU, Bell W, Sinclair S. Pathophysiology of acute respiratory syndrome. Glucocorticoid receptor-mediated regulation of inflammation and response to prolonged glucocorticoid treatment. Presse Med 2011; 40:e543-e560.
4. Marik PE, Pastores SM, Annane D. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: concensus statement from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937-1949.
5. Cronin L, Cook DJ, Carlet J. Corticosteroid treatment in sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 24:1430-1439.
6. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
7. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-650.
8. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, singlecenter study. Crit Care Med 1999; 27:723-732.
9. Chawla K, Kupfer Y, Goldman I. Hydrocortisone reverses refractory septic shock. Crit Care Med 1999; 27:A33.
10. Oppert M, Schindler R, Husung C, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005; 33:2457-2464.
11. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008; 34:17-60.
12. Sprung CL, Annane D, Keh D, et al. For the corticus study group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
13. Sligl WI, Milner DA Jr, Sundar S, et al. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin Infect Dis 2009; 49:93-101.
14. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301:2362-2375.
15. Annane D, Cariou A, Maxime V, et al. COIITSS Study Investigators, Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303:341-348.
16. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37:811-818.
17. Arabi YM, Aljumah A, Dabbagh O. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ 2010; 182:1971-1977.
18. Payen JF, Dupuis C, Trouve-Buisson T. Corticosteroids after etomidate in critically ill patients: a randomized controlled tial. Crit Care Med 2012; 40:29-35.
19. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-650.
20. Rubenfed GD, Herridges MS. Epidemiology and outcomes of acute lung injury. Chest 2007; 131:554-562.
21. Bernard GR, Luce JM, Sprung CL. High-Dose corticosteroids in patients with the adult respiratory distress syndrome. NEJM 1987; 317:1565-1570
22. Meduri GU, Golden E, Freire AX. Methylprednisolone infusion in early severe ARDS. Chest 2007; 131:954-963
23. Seam N, Meduri GU, Wang H. Effects of methylprednisolone infusion of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med 2012; 40:495-501.
24. Agarwal R, Nath A, Aggarwal AN. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007; 12:585-590.
25. Peter VJ, John P, Graham PL. Corticosteroids in the prevention and treatment of acute respiratory distress sybdrome in adults: metaanalysis. BMJ 2008; 336:1006-1009.
26. Meduri GU, Headley AS, Golden E. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized control trial. JAMA 1998; 280:159-165.
27. Steinberg KP, Hudson LD, Goodman RB. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684.
28. Tang BMP, Craig JC, Eslick GD. Use of corticosteroids in acute lung injury and acute respiratory distress sybdrome: a systematic review and metaanalysis. Crit Care Med 2009; 37:1594-1603.
29. Meduri GU, Marik PE, Chrousos GP. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34:61-69.
30. Lamontagne F, Briel M, Guyatt GH. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome and severe pneumonia: a metaanalysis of randomized controlled trials. J Crit Care 2010; 25:420-435.
31. Meduri GU, Bell W, Scott S. Pathology of acute repiratory distress syndrome. Glucocorticoid receptor of inflammation and response to prolonged glucocorticoid treatment. Presse Med 2011; 40:e543-e560.
32. Marik PE, Meduri GU, Rocco PR. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin 2011; 27:589-607.
33. Ventilation with low tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory distress Syndrome Network. N Engl J Med 2000; 342:1301-1308.
34. Ranieri VM, Rubenfeld GD, Thompson BT, ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307:2526-2533.
35. Mauad T, Hajjar LA, Callegari GD. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Resp Crit Care Med 2010; 181:72-79.
36. Quispe-Laime AM, Bracco JD, Barberio PA. H1N1 influenza A virus-associated lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010; 36:33-41.
37. Brun-Buisson C, Richard JC, Mercat A. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:1200-1206.
38. Martin-Loeches I, Lisboa T, Rhides A. Use of corticosteroid therapy in patients affected by severe pandemic H1N1 v Influenza A infection. Intensive Care Med 2011; 37:272-283.
39. Fine MJ, Smith MA, Carson CA. Prognosis an outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134-141.
40. Antunes G, Evans SA, Lordan JL. Systemic cytokine levels in communityacquired pneumonia and their association with disease severity. Eur Resp J 2002; 20:990-995.
41. Confalonieri M, Urbino R, Piatella M. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242-248.
42. Meijvis SCA, Hardeman H, Remmelts HHF. Dexamethasone and length of stay in patients with community-acquired pneumonia: a randomised doubleblind, placebo-controlled trial. Lancet 2011; 377:2023-2030.
43. Fernandez-Serrano S, Dorca J, Garcia-Vidal C. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15:R96.
44. Salluh JI, Soares M, George RC. Impact of systemic corticosteroids on the clinical course and outcomes of patients wih severe community-acquired pneumonia: a cohort study. J Crit Care 2011; 26:193-200.
45. Snijders D, Daniel JM, de Graaf CS. Efficacy of corticosteroids in communityacquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975.
46. Branco RG, Tasker RC. Meningococcal Meningitis. Curr Treatment Option Neurol 2010; 12:464-474.
47. Brouwer MC, McIntyre P, de Gans J et al. Corticosteroids for acute bacterial meningitis, Cochrane Database Syst Rev. 2010:CD004405
48. van der Beek D, Farrar JJ, de Gans J et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010; 9:254-263.
49. McIntyre P. Adjunctive dexamethasone in meningitis: does value depend on clinical setting? Lancet Neurol 2010; 9:229-231.
50. Gordon SB, Walsh AL, Chaponda M, et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe and seasonal. Clin Inf Dis 2000; 31:53-57.
51. Markandaya M, Stein DM, Menaker J. Acute treatment options for spinal cord injury. Curr Treat Options Neurol 2012; 14:175-187.
52. Bracken MB, Shepard MJ, Collins WF Jr. Methylprednisolone o naloxone treatment after acute spinal cord injury: 1 year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 1992; 76:23.
53. Bracken MB, Shepard MJ, Holford TR. Methylprednisolone or tirikazad nesylate admistration after acute spinal cord injury: 1 year follow-up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998; 89:699.
54. Qian T, Guo X, Levi AD. High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 2005; 43:199-203.
55. Felleiter P, Mü ller N, Schumann F. Changes in the use of the methylprednisolone protocol for traumatic spinal cord injury in Switzerland. Spine 2012; 37: 953-956.
56. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 2012 Jan 18; 1: CD001046.
57. Roberts I, Yates D, Sandercock P. Effect of intravenous coricosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomized placebo-controlled trial. Lancet 2004; 364:1321-1328.